. Author manuscript; available in PMC: 2013 Sep 1.

Published in final edited form as: Pediatr Hematol Oncol. 2012 Jul 27;29(6):568–578. doi: 10.3109/08880018.2012.708708

Table II. Outcomes of Interest.

This table shows post-transplant outcomes in three patients treated on this protocol. N/E: not evaluable; N/A: not applicable

Patient	Day of engraftment	Day platelet transfusion independent	Mucositis	CD 3 Chimerism			Acute GVHD?	Treatment for acute GVHD	Chronic GVHD?	Treatment for chronic GVHD	Karnofsky score at last follow-up	Last follow-up	Additional comments
Patient	Day of engraftment	Day platelet transfusion independent	Mucositis	1 mo	6 mo	12 mo	Acute GVHD?	Treatment for acute GVHD	Chronic GVHD?	Treatment for chronic GVHD	Karnofsky score at last follow-up	Last follow-up	Additional comments
1	+15	N/E	Grade 3b	100%/ 100% (CD33)	N/E	N/E	No	N/A	N/A	N/A	N/E	Day +37	Patient died at day +37 from disseminated toxoplasmosis and CMV; no GVHD was seen on autopsy

2	+16	+25	Grade 3b	100%/100%(CD33)	100%	100%	Yes Grade II (gut)	Cyclosporine continued. Added Beclomethasone	No	N/A	100%	3 yrs	Doing well, transfusion independent, no secondary malignancies
3	+14	+29	Grade 2	100%/100%(CD33)	100%	100%	Yes Grade III (skin, gut, liver)	Cyclosporine continued. Added Prednisone Basiliximab	Yes, extensive (oral and pulmonary)	Cyclosporine continued, Prednisone, Oral MMF	90%	2 yrs	Doing well with active chronic GVHD of oral mucosa, transfusion independent, no secondary malignancies